AstraZeneca Terminates Volrustomig Lung Cancer Trial, Analysts Estimate ~$1.3 Billion Valuation Loss
Nashnova编辑部
AstraZeneca halted its Phase III lung-cancer trial of volrustomig after an independent panel found the drug underperformed Merck's Keytruda. This means → the ~$1.3 billion in peak sales analysts had projected is now off the table.
Why was the trial stopped?
The Independent Data Monitoring Committee (IDMC — a third-party body that reviews data while a trial is running) concluded that volrustomig plus chemotherapy fell short of Keytruda plus chemotherapy in patients with PD-L1-low tumors.
In plain terms = the new drug lost the head-to-head against the existing gold standard, making it pointless to continue.
The IDMC determined the trial was unlikely to meet its pre-set endpoints and recommended termination. The trial was designated eVOLVE-Lung02.
Where did the $1.3 billion estimate come from — and where did it go?
According to Bloomberg's consensus, analysts had projected volrustomig to generate ~$1.3 billion in sales by 2032, with lung cancer as its largest indication.
This means → terminating the lung-cancer trial removes the core pillar of that valuation; whether the remaining indications can fill the gap is unclear.
This reflects a broader fragility in pharma valuations built on pipeline expectations — one failed Phase III trial can zero out billions of dollars in forward revenue assumptions.
Were there safety concerns? Are other trials still running?
AstraZeneca said the safety profile of volrustomig plus chemotherapy was consistent with the known profiles of both drugs, with no new safety signals.
In plain terms = the trial was stopped because the drug didn't work well enough, not because it was unsafe.
The termination is limited to eVOLVE-Lung02 only. Volrustomig's other Phase III trials — in cervical cancer, head-and-neck cancer, and mesothelioma — continue as planned.
What does this mean for AstraZeneca?
AstraZeneca has built a dominant oncology franchise in recent years on blockbusters such as Tagrisso and Imfinzi; this trial failure is a setback.
This means → the market will now watch volrustomig's remaining indications closely to see whether they can offset the lung-cancer gap.
Lung cancer is one of the world's largest oncology-drug markets. Losing this ticket matters beyond a single molecule — it raises questions about whether AstraZeneca's growth narrative in oncology remains intact.
Content is for reference only, not financial advice.